The MIF is uniquely positioned to identify and invest in the most promising new therapies in development – and to identify innovative technologies that could change the landscape of myeloma research. Our investments are driven by our singular goal to accelerate the development of novel therapies which could lead to cures for each and every multiple myeloma patient.
We look for companies pairing great science and a strong potential for transformative patient benefit with the potential for a significant financial return to drive the MIF’s growth and sustainability. Importantly, as a philanthropic venture fund, 100% of our financial returns are reinvested into the fund to continue supporting the development of future myeloma therapies.
Learn More About our investment strategy